Vitamin China E-News 1703 - Monthly Market Report
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Vitamins China E-News provides you with real-time intelligence on Chinas vitamins market.
It is a monthly published newsletter, which can be downloaded in PDF format. The subscription period is yearly, grants the subscriber 12 issues in total.
China is the worlds largest exporter of vitamins, while the domestic market has also expanded rapidly in recent years thanks to growing demand from the feed and pharmaceuticals markets. Now, competition in the industry is shifting from producing API to higher-margin pharmaceutical-grade products, while Chinas tougher stance on environmental protection is also having an effect.
Vitamins China E-News will help you stay ahead of the game in this fast-changing market with real-time reporting on the entire vitamins industry chain, from raw materials to end consumption. This includes:
Breaking news from China and abroad
The latest market data, including price information for raw materials, intermediates and end products, import/export data, production, consumption, operating rates, etc.
In-depth analysis of market trends, Chinese government policy, the performance of leading Chinese producers, M&A, new technologies, and more
Expert commentary from industry insiders, including regular guest articles and interviews with insiders at leading Chinese manufacturers, associations and government organizations"
Headlines
On 4 March, 2017, the 9th National Pharmaceuticals Industry Symposium was held in Beijing. At the conference, deputies suggested relaxing production license regulation or introducing DMF system in order to depress the price hikes in APIs like vitamins. If implemented, the monopolised vitamin API manufacturing industry may be impacted to some extent.
VB prices are expected to keep high in the Chinese market in H1 2017, mainly due to increasing raw material prices, strengthened environmental regulations, and raised quotations from leading producers. Yet, VB3 and VB5 prices may fall slightly in H2, as new production projects are put into production.
In early 201 7, many Chinese producers of vitamin functional beverages launched their new products to capture larger market shares, intensifying the market competition.
Brother Enterprises recorded significant financial growth in 2016, mainly thanks to the increased sales prices of VB1 and VB3. On 20 March, 2017, CSPC Pharmaceutical issued its 201 6 financial report, indicating a YoY growth of 26.20% in net profit due to the increased finished drug sales and financial turnaround in VC business.
On 28 Feb., 2017, Guangji Pharmaceutical announced significant rises in 2016 financial performance, mainly thanks to the increased sales of its VB2 and VB6. As national environmental regulations become more stringent and production further concentrated, the company is likely to continue making great achievements in VB2 and VB6 businesses in 2017.
In March, 2017, Nenter completed trial production of its 20,000 t/a VE project and has already had products available to the market. As more new projects are put into production and supply increases, the domestic VE market kept fluctuating in early 2017. Yet, Nenter is still expected to profit from its VE business given its competitive production costs.
Exports of VB1 from China are estimated to increase just slightly in 2017, given the stable domestic production and overseas demand. As the environmental policies become more stringent, domestic producers are confronted with increased production costs, and show weak inclination to expand production.
Affected by continual environmental pressure in 2017, leading VC producers CSPC Pharmaceutical and North China Pharmaceutical planned to cut production, further tightening the market supply. Meanwhile, demand for VC is expected to be boosted by seasonal sales peak in the livestock market. For these reasons, VC price may keep high in H1 , but is likely to fluctuate in H2 as Northeast Pharmaceutical puts its new production project into operation.
In recent two years, the price of VD3 has been down (Feb. 2017 saw price down of 22.62% year on year). Under the stricter environmental regulations, downward price will inevitably intensify concentration ratio, so for the sake of balance between cost and profit, the price of VD is expected to go up.
It is a monthly published newsletter, which can be downloaded in PDF format. The subscription period is yearly, grants the subscriber 12 issues in total.
China is the worlds largest exporter of vitamins, while the domestic market has also expanded rapidly in recent years thanks to growing demand from the feed and pharmaceuticals markets. Now, competition in the industry is shifting from producing API to higher-margin pharmaceutical-grade products, while Chinas tougher stance on environmental protection is also having an effect.
Vitamins China E-News will help you stay ahead of the game in this fast-changing market with real-time reporting on the entire vitamins industry chain, from raw materials to end consumption. This includes:
Breaking news from China and abroad
The latest market data, including price information for raw materials, intermediates and end products, import/export data, production, consumption, operating rates, etc.
In-depth analysis of market trends, Chinese government policy, the performance of leading Chinese producers, M&A, new technologies, and more
Expert commentary from industry insiders, including regular guest articles and interviews with insiders at leading Chinese manufacturers, associations and government organizations"
Headlines
On 4 March, 2017, the 9th National Pharmaceuticals Industry Symposium was held in Beijing. At the conference, deputies suggested relaxing production license regulation or introducing DMF system in order to depress the price hikes in APIs like vitamins. If implemented, the monopolised vitamin API manufacturing industry may be impacted to some extent.
VB prices are expected to keep high in the Chinese market in H1 2017, mainly due to increasing raw material prices, strengthened environmental regulations, and raised quotations from leading producers. Yet, VB3 and VB5 prices may fall slightly in H2, as new production projects are put into production.
In early 201 7, many Chinese producers of vitamin functional beverages launched their new products to capture larger market shares, intensifying the market competition.
Brother Enterprises recorded significant financial growth in 2016, mainly thanks to the increased sales prices of VB1 and VB3. On 20 March, 2017, CSPC Pharmaceutical issued its 201 6 financial report, indicating a YoY growth of 26.20% in net profit due to the increased finished drug sales and financial turnaround in VC business.
On 28 Feb., 2017, Guangji Pharmaceutical announced significant rises in 2016 financial performance, mainly thanks to the increased sales of its VB2 and VB6. As national environmental regulations become more stringent and production further concentrated, the company is likely to continue making great achievements in VB2 and VB6 businesses in 2017.
In March, 2017, Nenter completed trial production of its 20,000 t/a VE project and has already had products available to the market. As more new projects are put into production and supply increases, the domestic VE market kept fluctuating in early 2017. Yet, Nenter is still expected to profit from its VE business given its competitive production costs.
Exports of VB1 from China are estimated to increase just slightly in 2017, given the stable domestic production and overseas demand. As the environmental policies become more stringent, domestic producers are confronted with increased production costs, and show weak inclination to expand production.
Affected by continual environmental pressure in 2017, leading VC producers CSPC Pharmaceutical and North China Pharmaceutical planned to cut production, further tightening the market supply. Meanwhile, demand for VC is expected to be boosted by seasonal sales peak in the livestock market. For these reasons, VC price may keep high in H1 , but is likely to fluctuate in H2 as Northeast Pharmaceutical puts its new production project into operation.
In recent two years, the price of VD3 has been down (Feb. 2017 saw price down of 22.62% year on year). Under the stricter environmental regulations, downward price will inevitably intensify concentration ratio, so for the sake of balance between cost and profit, the price of VD is expected to go up.
TABLE OF CONTENTS
Headline
Editors Note
1. Governmental Direction
1.1 Chinese drug producers call for antitrust actions against surging vitamin prices
2. Market Dynamics
2.1 Chinas VB prices likely to stay high in H1 2017
2.2 Vitamin functional drink business: diversifying products and intensifying competition
3. Company Developments
3.1 Brother Enterprises: +103.87% YoY in 2016 net profit
3.2 CSPC Pharmaceutical turns VC business around in 2016
3.3 Guangji Pharmaceutical: significant financial growth in 2016
3.4 Nenter completes VE trial production
4. Import and Export Analysis
4.1 Imports & exports of selected vitamins in China, Jan. 2017
4.2 VB1 exports from China likely to increase slightly in 2017
5. Price Update
5.1 Market prices of selected vitamins in China,March 2017
5.2 Chinese VC market price to remain upward in H1 2017
5.3 Price of VD3 expected to go up
6. News in Brief
6.1 Zhejiang NHU: significant financial growth in 2016
6.2 Yifan Pharmaceutical: +95.23% YoY in 2016 net profit
6.3 Kingdomway terminates acquisition of YKS
6.4 Lanbo Biotechnology suspends production from March 20
6.5 Huisheng Pharmaceutical obtains high-tech enterprise certification
6.6 Xinfa Pharmaceutical to apply for retrial
6.7 North China Pharmaceutical: net profit 2016 down 13.42% YoY
6.8 Zhejiang Tianxin raises VB1 quotation
6.9 Zhenhua Chemicals director resigns
6.10 Mr. Qian Zhida holds another 20 million shares of Brother Enterprises
Editors Note
1. Governmental Direction
1.1 Chinese drug producers call for antitrust actions against surging vitamin prices
2. Market Dynamics
2.1 Chinas VB prices likely to stay high in H1 2017
2.2 Vitamin functional drink business: diversifying products and intensifying competition
3. Company Developments
3.1 Brother Enterprises: +103.87% YoY in 2016 net profit
3.2 CSPC Pharmaceutical turns VC business around in 2016
3.3 Guangji Pharmaceutical: significant financial growth in 2016
3.4 Nenter completes VE trial production
4. Import and Export Analysis
4.1 Imports & exports of selected vitamins in China, Jan. 2017
4.2 VB1 exports from China likely to increase slightly in 2017
5. Price Update
5.1 Market prices of selected vitamins in China,March 2017
5.2 Chinese VC market price to remain upward in H1 2017
5.3 Price of VD3 expected to go up
6. News in Brief
6.1 Zhejiang NHU: significant financial growth in 2016
6.2 Yifan Pharmaceutical: +95.23% YoY in 2016 net profit
6.3 Kingdomway terminates acquisition of YKS
6.4 Lanbo Biotechnology suspends production from March 20
6.5 Huisheng Pharmaceutical obtains high-tech enterprise certification
6.6 Xinfa Pharmaceutical to apply for retrial
6.7 North China Pharmaceutical: net profit 2016 down 13.42% YoY
6.8 Zhejiang Tianxin raises VB1 quotation
6.9 Zhenhua Chemicals director resigns
6.10 Mr. Qian Zhida holds another 20 million shares of Brother Enterprises
RELATED REPORTS
Crop Farming China E-News 1703 - Monthly Market Report
Crop Farming China News provides you with real-time intelligence on Chinas agricultural commoditiesmarkets.It is a monthly published newsletter, which can be downloaded in PDF format. The subscription period is yearly,
View ReportAmino Acids China E-News 1703 - Monthly Market Report
Amino Acids China E-News provides you with real-time intelligence on Chinas amino acids market.It is a monthly published newsletter, which can be downloaded in PDF format. The subscription period is
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
